AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Cumberland Pharmaceuticals Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001STBRH3
8.49▲ 0.01 (0.12%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
8.48
Day's Range
8.33 – 8.76
52-Week Range
1.85 – 9.28
Volume
18.7K
Avg Volume
48.1K
Share Statistics
Shares Outstanding
Employees
93
Exchange
XNAS
Listed
2009-08-11
Share count as of August 5, 2026

Cumberland Pharmaceuticals Inc (CPIX) Financial Statements

Akyla Research covers Cumberland Pharmaceuticals Inc. — read the latest report (June 17, 2026)

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cumberland Pharmaceuticals Inc (CPIX)
What is Cumberland Pharmaceuticals Inc's Market Cap?
Cumberland Pharmaceuticals Inc's Market Cap is $127.2M, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's Enterprise Value?
Cumberland Pharmaceuticals Inc's Enterprise Value is $123.3M, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's Price / Sales?
Cumberland Pharmaceuticals Inc's Price / Sales is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's EV / Revenue?
Cumberland Pharmaceuticals Inc's EV / Revenue is 3.1×, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's EV / EBITDA?
Cumberland Pharmaceuticals Inc's EV / EBITDA is 112.5×, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's Revenue (TTM)?
Cumberland Pharmaceuticals Inc's Revenue (TTM) is $39.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's Net Income (TTM)?
Cumberland Pharmaceuticals Inc's Net Income (TTM) is -$10.9M, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's EBITDA?
Cumberland Pharmaceuticals Inc's EBITDA is $1.1M, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's Diluted EPS (TTM)?
Cumberland Pharmaceuticals Inc's Diluted EPS (TTM) is -0.73, based on as-reported figures from SEC (XBRL) filings.
What is Cumberland Pharmaceuticals Inc's EBITDA Margin?
Cumberland Pharmaceuticals Inc's EBITDA Margin is 2.7%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CPIXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenues from continuing operations———
YoY growth-56.3%———
Costs and expenses:
Research and development
General and administrative
Amortization
Total costs and expenses
% of revenue1998.7%———
Operating loss
% of revenue-1898.7%———
Interest income
Interest expense
Loss before income taxes—
Income tax expense
Net loss from continuing operations———
Net income (loss)
% of revenue-2567.9%———
Net income (loss) at subsidiary attributable to noncontrolling interests
Net income (loss) attributable to common shareholders
% of revenue-2569.0%———
Income (loss) per share attributable to common shareholders
Basic (in USD per share)
Diluted (in USD per share)